USV Private Limited Market Research Report

Company Overview

• Name: USV Private Limited

• Mission:

• To continue being recognized as a reliable provider of healthcare products and services worldwide.

• To provide superior value to customers and stakeholders through innovation, focus, and specialization.

• To create and sustain a work environment that values people, promotes learning, nurtures innovation, and leads to collective excellence.

• Founded: Established in 1961 as a joint venture with USV & P Inc. USA, a subsidiary of Revlon.

• Key People: No information is available.

• Headquarters: No information is available.

• Number of Employees: 163 employees are involved in biosimilar research, development, and manufacturing.

• Revenue: No information is available.

• Known For:

• Leadership in the Oral Anti-Diabetic market in India, ranking #1 by Rx and value.

• Leadership in Cardiology prescriptions in India.

• Comprehensive healthcare solutions, particularly in Active Pharmaceutical Ingredients (APIs), Peptides, Biosimilars, Injectables, Ophthalmics, and Solid Oral products.

Products

• Active Pharmaceutical Ingredients (APIs):

• Offers a broad range of 51 small molecule APIs.

• Collaboration with international markets through various drug master files.

• Biosimilars:

• Portfolio includes biosimilar products developed using recombinant technology.

• Manufacturing facilities certified by EU GMP, WHO GMP, and other international regulatory bodies.

• Injectables:

• Range includes small molecules, peptides, and recombinant proteins.

• Manufactured in sterile 'Fill & Finish' plants.

• Ophthalmics:

• Products include Olopatadine Hcl ophthalmic solutions with varying strengths.

• Peptides:

• Commercially available products include Octreotide, Icatibant, and Etelcalcetide.

• Solid Orals:

• Products comprise immediate release and complex modified release formulations.

Key Features of Products

• APIs: Aggressive development program, aiming to be a reliable and responsive partner in the international market.

• Biosimilars: Focus on biologics with a fully functional GMP facility, investment in research and development.

• Injectables: Diverse portfolio with a focus on regulatory compliance and international market penetration.

• Ophthalmics: Strong presence in both developed and emerging markets, with good regulatory approvals and market authorizations.

• Peptides: Investment in R&D and technological infrastructure, ensuring high-quality peptide products.

• Solid Orals: Manufactured in cGMP compliant plants, featuring advanced technological infrastructure for development and manufacturing.

Recent Developments

• Board Expansion: Announced an expansion in the USV Board of Directors with the addition of Dr. Aneesha Gandhi Tewari.

• Product Approval: USV's Peg GCSF approved in the Australian market under the brand name Filpegla.

• Market Authorization: Obtained marketing authorization for Vildagliptin & Pioglitazone tablets for domestic use through in-house development.

• Product Launch: Launched UDAPA S - a fixed dose combination of Dapagliflozin and Sitagliptin.

• Manufacturing Milestones: The Vadodara state-of-the-art formulation plant commenced commercial supplies in July 2022 for Glycomet GP.

• Partnerships: Ongoing collaborations with global pharmaceutical companies, emphasizing in-licensing and joint product development ventures.

Conclusion

USV Private Limited has effectively reinforced its position as a prominent player in the healthcare industry, spearheading growth in major pharmaceutical sectors and consistently innovating within its product offerings. The facilitating of advanced R&D initiatives and alignment with global regulatory standards underscore its commitment to delivering high-quality healthcare solutions across diverse markets.